申请人:Merck Sharp & Dohme Corp.
公开号:US11091806B2
公开(公告)日:2021-08-17
The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.
本发明提供了人类 1 号染色体上与 CRTH2 受体拮抗剂有益反应相关的遗传标记。这些 CRTH2 受体拮抗剂应答标记物主要用于鉴定最有可能从 CRTH2 受体拮抗剂组合物和药物产品的治疗中获益的患者,用于治疗易患 CRTH2 受体拮抗剂治疗疾病的患者的方法,以及用于为这类患者选择最合适疗法的方法。